Are Investors Fleeing Third Wave Just As Long-Term Strategy Gains Traction? | GenomeWeb

Third Wave Technologies stockholders have been slowly turning their back on the company after it said that fourth-quarter revenues fell by 16.5 percent atop nearly tripled losses.

But are the shareholders, who have caused Third Wave's stock to shed nearly one-third of its market capitalization in 11 trading days, retreating just as the company's long-term growth strategy starts to gain traction?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.